

be performed efficiently. Additionally, there is a growing demand for comprehensive diagnostic tests that can detect multiple infections in a single test, further enhancing the preference for laboratory testing. With their reliable results and high diagnostic capabilities, laboratory tests offer an effective solution for detecting infectious diseases.

“The multiplex testing segment accounted for the largest market share, by type, in 2025.”

The global market for molecular infectious disease testing can be divided into two main segments: singleplex testing and multiplex testing. Among these, multiplex testing leads the market due to its ability to run multiple tests simultaneously, enabling the detection and differentiation of various pathogens in a single test. This capability not only saves time, money, and effort but also makes it the preferred choice for healthcare providers. Additionally, the rise in co-infections, the need for comprehensive diagnostic tests, and the demand for accurate results in shorter timeframes have all contributed to the growth of the multiplex testing market.

“The Asia Pacific is the fastest-growing market for molecular infectious disease testing during the forecast period.”

The global market for molecular infectious disease testing is segmented into the following regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC countries. The market is experiencing significant growth, particularly in the Asia Pacific region, driven by the high prevalence of infectious diseases in densely populated areas. There is a growing emphasis on early disease detection, which increases the demand for advanced diagnostic tools. Government and healthcare organizations are making substantial investments to enhance healthcare infrastructure, improve diagnostic facilities, and support research initiatives. Additionally, a focus on disease surveillance, outbreak management, and increased healthcare expenditure further contributes to the Asia Pacific region's significant role in the overall growth of the molecular infectious disease testing market.

The breakdown of the profile of primary participants in the molecular infectious disease testing market is:

By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)

By Designation: C-level Executives (27%), Directors (18%), and Other

Designations (55%)

By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)

The key players in the molecular infectious disease testing market are Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Bruker (US), Seegene Inc. (South Korea), Genetic Signatures (Australia), Co-Diagnostics, Inc. (US), Savyon Diagnostics (Israel), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), Uniogen OY (Finland), geneOmbio Technologies (India), Advanced Molecular Diagnostics (UK), GeneFirst Limited (UK), and Altona Diagnostics GmbH (Germany).

Research Coverage:

This research report categorizes the molecular infectious disease testing market by product & service (reagents & kits, instruments, and services & software), by type (singleplex testing and multiplex testing), by test type (laboratory tests and point-of-care tests), by disease [respiratory infectious diseases (influenza, tuberculosis, pharyngitis, and other respiratory infectious diseases), gastrointestinal infectious diseases (hepatitis and other gastrointestinal infectious diseases), sexually transmitted diseases (human immunodeficiency virus, chlamydia trachomatis, neisseria gonorrhoea, syphilis, human papillomavirus, and other sexually transmitted diseases), vaginitis, meningitis, vector-borne diseases, hospital-acquired infections, and other infectious diseases], by technology (polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, DNA microarrays, and other technologies), by end user (diagnostic laboratories, hospitals & clinics, and other end users), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and the GCC countries).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the molecular infectious disease testing market. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the molecular infectious disease testing market. This

report covers the competitive analysis of upcoming startups in the molecular infectious disease testing market ecosystem.

Reasons to buy this report:

The report will provide market leaders and newcomers with valuable insights into the revenue figures for the overall molecular infectious disease testing market and its subsegments. It will help stakeholders comprehend the competitive landscape, enabling them to better position their businesses and formulate effective go-to-market strategies. Additionally, the report will offer insights into the current market dynamics, highlighting key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (growing global infectious disease burden, advancements in molecular diagnostic technologies, growing funding for molecular testing, and growing awareness of early disease detection), restraints (lack of standardized reimbursement structures and high cost of instruments and consumables), opportunities (expansion potential across emerging economies, rising demand for point-of-care (POC) testing), and challenges (stringent and varying regulatory requirements, operational barriers and labor shortage challenges, and supply chain disruptions for reagents and kits) influencing the growth of the molecular infectious disease testing market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular infectious disease testing market.

Market Development: Comprehensive information about lucrative markets; the report analyzes the molecular infectious disease testing market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular infectious disease testing market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Hologic, Inc. (US), and Abbott

(US).

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
 - 1.3.1 MARKETS COVERED & REGIONAL SCOPE
 - 1.3.2 INCLUSIONS & EXCLUSIONS
 - 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

- 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
- 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

- 3.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET OVERVIEW
- 3.2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031
- 3.3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2026 VS. 2031
- 3.4 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2026 VS. 2031
- 3.5 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2026 VS. 2031
- 3.6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2026 VS. 2031
- 3.7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2026 VS. 2031
- 3.8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

4.1 INTRODUCTION

4.2 MARKET DYNAMICS

4.2.1 DRIVERS

- 4.2.1.1 Growing global infectious disease burden
- 4.2.1.2 Advancements in molecular diagnostic technologies
- 4.2.1.3 Growing funding for molecular testing
- 4.2.1.4 Growing awareness of early disease detection

4.2.2 RESTRAINTS

- 4.2.2.1 Lack of standardized reimbursement structures
- 4.2.2.2 High cost of instruments and consumables

4.2.3 OPPORTUNITIES

- 4.2.3.1 Expansion potential across emerging economies
- 4.2.3.2 Rising demand for point-of-care (POC) testing

4.2.4 CHALLENGES

- 4.2.4.1 Stringent and varying regulatory requirements
- 4.2.4.2 Operational barriers and labor shortage challenges
- 4.2.4.3 Supply chain disruptions for reagents and kits

4.3 UNMET NEEDS & WHITE SPACES

4.3.1 UNMET NEEDS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET

4.3.2 WHITE SPACE OPPORTUNITIES

4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES

4.4.1 INTERCONNECTED MARKETS

4.4.2 CROSS-SECTOR OPPORTUNITIES

4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS

4.5.1 KEY MOVES & STRATEGIC FOCUS

5 INDUSTRY TRENDS

5.1 PORTER'S FIVE FORCES ANALYSIS

5.1.1 BARGAINING POWER OF SUPPLIERS

5.1.2 BARGAINING POWER OF BUYERS

5.1.3 THREAT OF NEW ENTRANTS

5.1.4 THREAT OF SUBSTITUTES

5.1.5 INTENSITY OF COMPETITIVE RIVALRY

5.2 MACROECONOMIC INDICATORS

5.2.1 INTRODUCTION

- 5.2.2 GDP TRENDS & FORECAST
- 5.3 SUPPLY CHAIN ANALYSIS
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
 - 5.5.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
- 5.6 PRICING ANALYSIS
 - 5.6.1 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY KEY PLAYER, 2024–2026
 - 5.6.2 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2024–2026
- 5.7 TRADE ANALYSIS
 - 5.7.1 IMPORT SCENARIO (HS CODE 3822)
 - 5.7.2 EXPORT SCENARIO (HS CODE 3822)
- 5.8 KEY CONFERENCES & EVENTS, 2026–2027
- 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.10 INVESTMENT & FUNDING SCENARIO
- 5.11 IMPACT OF 2025 US TARIFFS ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET
 - 5.11.1 INTRODUCTION
 - 5.11.2 KEY TARIFF RATES
 - 5.11.3 PRICE IMPACT ANALYSIS
 - 5.11.4 IMPACT ON REGIONS
 - 5.11.4.1 North America
 - 5.11.4.2 Europe
 - 5.11.4.3 Asia Pacific
 - 5.11.5 IMPACT ON END-USE INDUSTRIES
 - 5.11.5.1 Diagnostic laboratories
 - 5.11.5.2 Hospitals & clinics
 - 5.11.5.3 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

- 6.1 KEY EMERGING TECHNOLOGIES
 - 6.1.1 NEXT-GENERATION SEQUENCING
 - 6.1.2 POLYMERASE CHAIN REACTION
- 6.2 COMPLEMENTARY TECHNOLOGIES
 - 6.2.1 BIOINFORMATICS & DATA ANALYTICS PLATFORMS

6.2.2 LABORATORY INFORMATION SYSTEMS (LIS) & DIGITAL HEALTH INTEGRATION

6.3 ADJACENT TECHNOLOGIES

6.3.1 CRISPR-BASED DIAGNOSTICS

6.3.2 DIGITAL PCR (DPCR)

6.4 TECHNOLOGY/PRODUCT ROADMAP

6.5 PATENT ANALYSIS

6.5.1 LIST OF MAJOR PATENTS

6.6 FUTURE APPLICATIONS

6.7 IMPACT OF AI/GENERATIVE AI ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET

6.7.1 INTRODUCTION

6.7.2 TOP USE CASES & MARKET POTENTIAL

6.7.3 KEY COMPANIES IMPLEMENTING AI

6.7.4 FUTURE OF AI

7 SUSTAINABILITY & REGULATORY LANDSCAPE

7.1 REGIONAL REGULATIONS & COMPLIANCE

7.1.1 REGULATORY ANALYSIS

7.1.1.1 North America

7.1.1.1.1 US

7.1.1.1.2 Canada

7.1.1.2 Europe

7.1.1.2.1 Germany

7.1.1.2.2 UK

7.1.1.2.3 France

7.1.1.2.4 Italy

7.1.1.3 Asia Pacific

7.1.1.3.1 China

7.1.1.3.2 Japan

7.1.1.3.3 India

7.1.1.3.4 Australia

7.1.1.4 Latin America

7.1.1.4.1 Brazil

7.1.1.4.2 Mexico

7.1.1.5 Middle East

7.1.1.5.1 Africa

7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER

ORGANIZATIONS

7.2 SUSTAINABILITY INITIATIVES

7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES

7.2.1.1 Eco-friendly initiatives

7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

8.1 DECISION-MAKING PROCESS

8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA

8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS

8.2.2 BUYING CRITERIA

8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES

8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES

8.5 MARKET PROFITABILITY

8.5.1 REVENUE POTENTIAL

8.5.2 COST DYNAMICS

8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE

9.1 INTRODUCTION

9.2 REAGENTS & KITS

9.2.1 ONGOING INNOVATIONS IN MOLECULAR DIAGNOSTICS TO SPUR GROWTH

9.3 INSTRUMENTS

9.3.1 TECHNOLOGICAL ADVANCEMENTS TO FOSTER GROWTH

9.4 SOFTWARE & SERVICES

9.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO FACILITATE GROWTH

10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE

10.1 INTRODUCTION

10.2 MULTIPLEX TESTING

10.2.1 RISING DEMAND FOR FASTER DIAGNOSIS TO PROMOTE GROWTH

10.3 SINGLEPLEX TESTING

10.3.1 NEED FOR AFFORDABLE AND USER-FRIENDLY TESTING TO AUGMENT

GROWTH

11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE

11.1 INTRODUCTION

11.2 LABORATORY TESTS

11.2.1 INCREASING NEED FOR AUTOMATION TO FAVOR GROWTH

11.3 POINT-OF-CARE TESTS

11.3.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET

12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE

12.1 INTRODUCTION

12.2 RESPIRATORY INFECTIOUS DISEASES

12.2.1 INFLUENZA

12.2.1.1 Growing focus on faster diagnosis and control to propel market

12.2.2 TUBERCULOSIS

12.2.2.1 Rise in undiagnosed and untreated cases to promote growth

12.2.3 PHARYNGITIS

12.2.3.1 Need to differentiate between bacterial and viral infections to fuel growth

12.2.4 NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS

12.2.4.1 Increasing reliance on advanced molecular diagnostic technologies to fuel growth

12.2.5 OTHER RESPIRATORY INFECTIOUS DISEASES

12.3 GASTROINTESTINAL INFECTIOUS DISEASES

12.3.1 HEPATITIS

12.3.1.1 Rising global incidence of infections to expedite growth

12.3.2 OTHER GASTROINTESTINAL INFECTIOUS DISEASES

12.4 SEXUALLY TRANSMITTED DISEASES

12.4.1 HUMAN IMMUNODEFICIENCY VIRUS

12.4.1.1 Increasing number of blood transfusions and blood donations to augment growth

12.4.2 HUMAN PAPILLOMAVIRUS

12.4.2.1 Technological advancements for preventing human papillomavirus infections to drive market

12.4.3 CHLAMYDIA TRACHOMATIS

12.4.3.1 Increasing incidence of chlamydia to aid growth

12.4.4 NEISSERIA GONORRHOEAE

12.4.4.1 Increasing development of novel assays to boost market

12.4.5 SYPHILIS

12.4.5.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market

12.4.6 OTHER SEXUALLY TRANSMITTED DISEASES

12.5 HOSPITAL-ACQUIRED INFECTIONS

12.5.1 GROWING BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TO FUEL MARKET

12.6 VAGINITIS

12.6.1 INCREASING AWARENESS ABOUT WOMEN'S HEALTH TO BOLSTER GROWTH

12.7 MENINGITIS

12.7.1 RISING INCIDENCE OF INVASIVE MENINGOCOCCAL DISEASE TO ASSIST GROWTH

12.8 VECTOR-BORNE DISEASES

12.8.1 GROWING FOCUS ON DISEASE SURVEILLANCE TO PROPEL MARKET

12.9 BLOODSTREAM INFECTIONS & SEPSIS

12.9.1 HIGH BURDEN OF BLOODSTREAM INFECTIONS TO PROPEL MARKET

12.10 OTHER INFECTIOUS DISEASES

13 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY

13.1 INTRODUCTION

13.2 POLYMERASE CHAIN REACTION

13.2.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH

13.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY

13.3.1 EMERGENCE OF NEW PATHOGENS TO STIMULATE GROWTH

13.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING

13.4.1 GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET

13.5 IN SITU HYBRIDIZATION

13.5.1 NEED FOR SAFER AND MORE PRACTICAL TESTING IN CLINICAL SETTINGS TO FUEL MARKET

13.6 DNA MICROARRAYS

13.6.1 NEED FOR AFFORDABLE AND SENSITIVE DETECTION TO ENCOURAGE GROWTH

13.7 OTHER TECHNOLOGIES

14 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER

14.1 INTRODUCTION

14.2 DIAGNOSTIC LABORATORIES

14.2.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET

14.3 HOSPITALS & CLINICS

14.3.1 RISING PATIENT VOLUMES TO CONTRIBUTE TO GROWTH

14.4 OTHER END USERS

15 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION

15.1 INTRODUCTION

15.2 NORTH AMERICA

15.2.1 US

15.2.1.1 Presence of advanced healthcare infrastructure to augment growth

15.2.2 CANADA

15.2.2.1 Favorable government initiatives to fuel market

15.3 EUROPE

15.3.1 GERMANY

15.3.1.1 Increasing healthcare expenditure to advance growth

15.3.2 UK

15.3.2.1 Growing number of diagnostic centers to fuel market

15.3.3 FRANCE

15.3.3.1 Increasing demand for early disease diagnosis to augment growth

15.3.4 ITALY

15.3.4.1 Growing adoption of advanced diagnostic technologies to fuel market

15.3.5 RUSSIA

15.3.5.1 Increasing access to quality healthcare to facilitate growth

15.3.6 SPAIN

15.3.6.1 Growing public health initiatives to boost market

15.3.7 REST OF EUROPE

15.4 ASIA PACIFIC

15.4.1 CHINA

15.4.1.1 Rising public access to modern healthcare to spur growth

15.4.2 JAPAN

15.4.2.1 Universal healthcare reimbursement policy to foster growth

15.4.3 INDIA

15.4.3.1 Increased private and public investments to bolster growth

15.4.4 AUSTRALIA

15.4.4.1 Growing investments for testing centers and treatment facilities to drive market

15.4.5 REST OF ASIA PACIFIC

15.5 LATIN AMERICA

15.5.1 BRAZIL

15.5.1.1 Growing focus on improving healthcare infrastructure to fuel market

15.5.2 MEXICO

15.5.2.1 Increasing accessibility and affordability of healthcare services to foster growth

15.5.3 REST OF LATIN AMERICA

15.6 MIDDLE EAST & AFRICA

15.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH

15.7 GCC COUNTRIES

15.7.1 GROWING PUBLIC HEALTHCARE FUNDING TO DRIVE MARKET

16 COMPETITIVE LANDSCAPE

16.1 INTRODUCTION

16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

16.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET

16.3 REVENUE ANALYSIS, 2023–2025

16.4 MARKET SHARE ANALYSIS, 2025

16.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025

16.4.2 US MARKET SHARE ANALYSIS, 2025

16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025

16.5.1 STARS

16.5.2 EMERGING LEADERS

16.5.3 PERVASIVE PLAYERS

16.5.4 PARTICIPANTS

16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025

16.5.5.1 Company footprint

16.5.5.2 Region footprint

16.5.5.3 Product & service footprint

16.5.5.4 Disease footprint

16.5.5.5 Test type footprint

16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025

16.6.1 PROGRESSIVE COMPANIES

- 16.6.2 RESPONSIVE COMPANIES
- 16.6.3 DYNAMIC COMPANIES
- 16.6.4 STARTING BLOCKS
- 16.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
 - 16.6.5.1 Detailed list of key startups/SMEs
 - 16.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
 - 16.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
- 16.7 COMPANY VALUATION & FINANCIAL METRICS
 - 16.7.1 FINANCIAL METRICS
 - 16.7.2 COMPANY VALUATION
- 16.8 BRAND/PRODUCT COMPARISON
- 16.9 COMPETITIVE SCENARIO
 - 16.9.1 PRODUCT LAUNCHES & APPROVALS
 - 16.9.2 DEALS
 - 16.9.3 EXPANSIONS

17 COMPANY PROFILES

- 17.1 KEY PLAYERS
 - 17.1.1 DANAHER
 - 17.1.1.1 Business overview
 - 17.1.1.2 Products offered
 - 17.1.1.3 Recent developments
 - 17.1.1.3.1 Product approvals
 - 17.1.1.3.2 Deals
 - 17.1.1.4 MnM view
 - 17.1.1.4.1 Key strengths
 - 17.1.1.4.2 Strategic choices
 - 17.1.1.4.3 Weaknesses & competitive threats
 - 17.1.2 F. HOFFMANN-LA ROCHE LTD.
 - 17.1.2.1 Business overview
 - 17.1.2.2 Products offered
 - 17.1.2.3 Recent developments
 - 17.1.2.3.1 Product launches & approvals
 - 17.1.2.3.2 Deals
 - 17.1.2.3.3 Expansions
 - 17.1.2.4 MnM view
 - 17.1.2.4.1 Key strengths
 - 17.1.2.4.2 Strategic choices

- 17.1.2.4.3 Weaknesses & competitive threats
- 17.1.3 BIOM?RIEUX
 - 17.1.3.1 Business overview
 - 17.1.3.2 Products offered
 - 17.1.3.3 Recent developments
 - 17.1.3.3.1 Product launches & approvals
 - 17.1.3.3.2 Deals
 - 17.1.3.4 MnM view
 - 17.1.3.4.1 Key strengths
 - 17.1.3.4.2 Strategic choices
 - 17.1.3.4.3 Weaknesses & competitive threats
- 17.1.4 HOLOGIC, INC.
 - 17.1.4.1 Business overview
 - 17.1.4.2 Products offered
 - 17.1.4.3 Recent developments
 - 17.1.4.3.1 Product approvals
 - 17.1.4.4 MnM view
 - 17.1.4.4.1 Key strengths
 - 17.1.4.4.2 Strategic choices
 - 17.1.4.4.3 Weaknesses & competitive threats
- 17.1.5 ABBOTT
 - 17.1.5.1 Business overview
 - 17.1.5.2 Products offered
 - 17.1.5.3 Recent developments
 - 17.1.5.3.1 Product approvals
 - 17.1.5.3.2 Deals
 - 17.1.5.4 MnM view
 - 17.1.5.4.1 Key strengths
 - 17.1.5.4.2 Strategic choices
 - 17.1.5.4.3 Weaknesses & competitive threats
- 17.1.6 THERMO FISHER SCIENTIFIC INC.
 - 17.1.6.1 Business overview
 - 17.1.6.2 Products offered
 - 17.1.6.3 Recent developments
 - 17.1.6.3.1 Product launches
 - 17.1.6.3.2 Deals
- 17.1.7 QIAGEN
 - 17.1.7.1 Business overview
 - 17.1.7.2 Products offered

- 17.1.7.3 Recent developments
 - 17.1.7.3.1 Product launches & approvals
 - 17.1.7.3.2 Deals
 - 17.1.7.3.3 Expansions
- 17.1.8 REVVITY
 - 17.1.8.1 Business overview
 - 17.1.8.2 Products offered
- 17.1.9 GRIFOLS, S.A.
 - 17.1.9.1 Business overview
 - 17.1.9.2 Products offered
 - 17.1.9.3 Recent developments
 - 17.1.9.3.1 Product approvals
- 17.1.10 SEEGENE INC.
 - 17.1.10.1 Business overview
 - 17.1.10.2 Products offered
 - 17.1.10.3 Recent developments
 - 17.1.10.3.1 Product approvals
 - 17.1.10.3.2 Deals
- 17.1.11 DIASORIN S.P.A.
 - 17.1.11.1 Business overview
 - 17.1.11.2 Products offered
 - 17.1.11.3 Recent developments
 - 17.1.11.3.1 Product approvals
 - 17.1.11.3.2 Deals
- 17.1.12 SIEMENS HEALTHINEERS AG
 - 17.1.12.1 Business overview
 - 17.1.12.2 Products offered
 - 17.1.12.3 Recent developments
 - 17.1.12.3.1 Deals
 - 17.1.12.3.2 Expansions
- 17.1.13 BECTON, DICKINSON AND COMPANY (BD)
 - 17.1.13.1 Business overview
 - 17.1.13.2 Products offered
 - 17.1.13.3 Recent developments
 - 17.1.13.3.1 Product approvals
 - 17.1.13.3.2 Deals
 - 17.1.13.3.3 Expansions
- 17.1.14 SD BIOSENSOR
 - 17.1.14.1 Business overview

- 17.1.14.2 Products offered
- 17.1.14.3 Recent developments
 - 17.1.14.3.1 Deals

17.2 OTHER PLAYERS

- 17.2.1 QUIDELORTHO CORPORATION
- 17.2.2 BRUKER
- 17.2.3 GENETIC SIGNATURES
- 17.2.4 CO-DIAGNOSTICS, INC.
- 17.2.5 VELA DIAGNOSTICS
- 17.2.6 MOLBIO DIAGNOSTICS PVT. LTD.
- 17.2.7 SAVYON DIAGNOSTICS
- 17.2.8 UNIOGEN OY
- 17.2.9 GENEOMBIO TECHNOLOGIES
- 17.2.10 ADVANCED MOLECULAR DIAGNOSTICS
- 17.2.11 ALTONA DIAGNOSTICS GMBH
- 17.2.12 GENEFIRST LIMITED

18 RESEARCH METHODOLOGY

18.1 RESEARCH DATA

18.2 SECONDARY DATA

- 18.2.1 LIST OF SECONDARY SOURCES
- 18.2.2 KEY DATA FROM SECONDARY SOURCES
- 18.2.3 PRIMARY DATA
 - 18.2.3.1 List of primary sources
 - 18.2.3.2 Key data from primary sources
 - 18.2.3.3 Key industry insights
 - 18.2.3.4 Breakdown of primary interviews

18.3 MARKET SIZE ESTIMATION

18.3.1 TOTAL MARKET SIZE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

18.3.2 BOTTOM-UP APPROACH

- 18.3.2.1 Approach 1: Revenue estimation of key players
- 18.3.2.2 Approach 2: Study of annual reports and investor presentations
- 18.3.2.3 Approach 3: Primary interviews
- 18.3.2.4 Growth forecast
- 18.3.2.5 CAGR projections

18.3.3 TOP-DOWN APPROACH

18.4 DATA TRIANGULATION

18.5 RESEARCH ASSUMPTIONS

18.5.1 STUDY-RELATED ASSUMPTIONS

18.6 STUDY ASSUMPTIONS

18.6.1 PARAMETRIC ASSUMPTIONS

18.6.2 GROWTH RATE ASSUMPTIONS

18.7 RESEARCH LIMITATIONS

18.8 RISK ASSESSMENT

19 APPENDIX

19.1 DISCUSSION GUIDE

19.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

19.3 RELATED REPORTS

19.4 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV, ALL AGES, 2010 VS. 2023 VS. 2024 (MILLION PEOPLE)

TABLE 2 TOTAL TB INCIDENCE, 2024

TABLE 3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS

TABLE 4 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030

TABLE 5 NORTH AMERICA: MACROECONOMIC INDICATORS

TABLE 6 EUROPE: MACROECONOMIC INDICATORS

TABLE 7 ASIA PACIFIC: MACROECONOMIC INDICATORS

TABLE 8 LATIN AMERICA: MACROECONOMIC INDICATORS

TABLE 9 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS

TABLE 10 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY KEY PLAYER, 2024–2026 (USD)

TABLE 11 AVERAGE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2024–2026 (USD)

TABLE 12 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)

TABLE 13 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)

TABLE 14 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: KEY CONFERENCES & EVENTS, 2026–2027

TABLE 15 US-ADJUSTED RECIPROCAL TARIFF RATES

TABLE 16 KEY PATENTS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2022–2026

TABLE 17 KEY COMPANIES IMPLEMENTING AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET

TABLE 18 CLASSIFICATION OF IVD DEVICES IN EUROPE

TABLE 19 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN

TABLE 20 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA

TABLE 21 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 22 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 23 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 24 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 25 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)

TABLE 27 KEY BUYING CRITERIA, BY PRODUCT & SERVICE

TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES

TABLE 29 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES

TABLE 30 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)

TABLE 31 KEY REAGENTS & KITS AVAILABLE IN MARKET

TABLE 32 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY REGION, 2024–2031 (USD MILLION)

TABLE 33 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 34 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 35 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 36 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 37 KEY INSTRUMENTS AVAILABLE IN MARKET

TABLE 38 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION)

TABLE 39 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 40 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 41 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 42 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 43 KEY SOFTWARE & SERVICES AVAILABLE IN MARKET

TABLE 44 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION)

TABLE 45 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)

- TABLE 46 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
- TABLE 47 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
- TABLE 48 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
- TABLE 49 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION)
- TABLE 50 KEY MULTIPLEX TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 51 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY REGION, 2024–2031 (USD MILLION)
- TABLE 52 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
- TABLE 53 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
- TABLE 54 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
- TABLE 55 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
- TABLE 56 KEY SINGLEPLEX TESTING PRODUCTS AVAILABLE IN MARKET
- TABLE 57 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY REGION, 2024–2031 (USD MILLION)
- TABLE 58 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
- TABLE 59 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
- TABLE 60 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
- TABLE 61 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2024–2031 (USD MILLION)
- TABLE 62 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
- TABLE 63 KEY LABORATORY-BASED TESTS AVAILABLE IN MARKET
- TABLE 64 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY REGION, 2024–2031 (USD MILLION)
- TABLE 65 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
- TABLE 66 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 67 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 68 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 69 KEY POINT-OF-CARE TESTS AVAILABLE IN MARKET

TABLE 70 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY REGION, 2024–2031 (USD MILLION)

TABLE 71 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 72 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 73 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 74 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 75 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION)

TABLE 76 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 77 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)

TABLE 78 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 79 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 80 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 81 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 82 KEY INFLUENZA TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 83 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY REGION, 2024–2031 (USD MILLION)

TABLE 84 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 85 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 86 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 87 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 88 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 89 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY REGION, 2024–2031 (USD MILLION)

TABLE 90 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 91 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 92 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 93 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 94 KEY PHARYNGITIS TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 95 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY REGION, 2024–2031 (USD MILLION)

TABLE 96 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 97 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 98 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 99 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 100 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY REGION, 2024–2031 (USD MILLION)

TABLE 101 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 102 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 103 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 104 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING

MARKET FOR NON-TUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 105 OTHER KEY RESPIRATORY INFECTION DISEASE TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 106 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)

TABLE 107 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 108 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 109 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 110 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 111 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 112 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)

TABLE 113 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 114 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 115 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 116 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 117 KEY HEPATITIS TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 118 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY REGION, 2024–2031 (USD MILLION)

TABLE 119 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 120 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 121 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 122 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 123 OTHER KEY GASTROINTESTINAL INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 124 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)

TABLE 125 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 126 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 127 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 128 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 129 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 130 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2024–2031 (USD MILLION)

TABLE 131 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 132 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 133 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 134 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031

(USD MILLION)

TABLE 135 KEY HIV TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 136 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY REGION, 2024–2031 (USD MILLION)

TABLE 137 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 138 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 139 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 140 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 141 KEY HUMAN PAPILLOMAVIRUS TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 142 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY REGION, 2024–2031 (USD MILLION)

TABLE 143 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 144 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 145 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 146 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 147 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 148 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2024–2031 (USD MILLION)

TABLE 149 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 150 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 151 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 152 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2024–2031 (USD

MILLION)

TABLE 153 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2024–2031 (USD MILLION)

TABLE 154 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEA, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 155 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 156 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 157 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 158 KEY SYPHILIS TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 159 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY REGION, 2024–2031 (USD MILLION)

TABLE 160 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 161 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 162 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 163 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 164 OTHER KEY SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 165 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY REGION, 2024–2031 (USD MILLION)

TABLE 166 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 167 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 168 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 169 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY,

2024–2031 (USD MILLION)

TABLE 170 KEY HOSPITAL-ACQUIRED INFECTION TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 171 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2024–2031 (USD MILLION)

TABLE 172 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 173 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 174 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 175 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 176 KEY VAGINITIS TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 177 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY REGION, 2024–2031 (USD MILLION)

TABLE 178 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 179 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 180 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 181 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 182 KEY MENINGITIS TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 183 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY REGION, 2024–2031 (USD MILLION)

TABLE 184 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 185 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 186 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 187 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 188 KEY VECTOR-BORNE DISEASE TESTING PRODUCTS AVAILABLE IN

MARKET

TABLE 189 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY REGION, 2024–2031 (USD MILLION)

TABLE 190 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 191 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 192 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 193 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 194 KEY BLOODSTREAM INFECTIONS & SEPSIS TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 195 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY REGION, 2024–2031 (USD MILLION)

TABLE 196 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 197 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 198 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 199 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR BLOODSTREAM INFECTIONS & SEPSIS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 200 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET

TABLE 201 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)

TABLE 202 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 203 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 204 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 205 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 206 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 207 KEY POLYMERASE CHAIN REACTION-BASED TESTS AND DEVICES AVAILABLE IN MARKET

TABLE 208 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2024–2031 (USD MILLION)

TABLE 209 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 210 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 211 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 212 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 213 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED TESTS AND DEVICES AVAILABLE IN MARKET

TABLE 214 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2024–2031 (USD MILLION)

TABLE 215 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 216 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 217 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 218 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 219 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION)

TABLE 220 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 221 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 222 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 223 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 224 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2024–2031 (USD MILLION)

TABLE 225 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 226 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 227 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 228 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 229 KEY MICROARRAY-BASED PRODUCTS AVAILABLE IN MARKET

TABLE 230 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY REGION, 2024–2031 (USD MILLION)

TABLE 231 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 232 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 233 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 234 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 235 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)

TABLE 236 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 237 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 238 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 239 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 240 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 241 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)

TABLE 242 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 243 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 244 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 245 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 246 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2024–2031 (USD MILLION)

TABLE 247 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 248 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 249 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 250 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 251 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)

TABLE 252 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 253 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 254 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 255 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 256 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION,

2024–2031 (USD MILLION)

TABLE 257 NORTH AMERICA: MACROECONOMIC INDICATORS

TABLE 258 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 259 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)

TABLE 260 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 261 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)

TABLE 262 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024–2031 (USD MILLION)

TABLE 263 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 264 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 265 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 266 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 267 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024–2031 (USD MILLION)

List Of Figures

LIST OF FIGURES

FIGURE 1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SEGMENTATION & REGIONAL SCOPE

FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS

FIGURE 3 GLOBAL MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2024–2031

FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023–2025

FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2025

FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

FIGURE 8 RISING CASES OF INFECTIOUS DISEASES TO DRIVE MARKET

FIGURE 9 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD

FIGURE 10 MULTIPLEX TESTING SEGMENT TO LEAD MARKET DURING FORECAST PERIOD

FIGURE 11 LABORATORY TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD

FIGURE 12 STDS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD

FIGURE 13 POLYMERASE CHAIN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD

FIGURE 14 DIAGNOSTIC LABORATORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD

FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

FIGURE 16 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 17 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 18 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS

FIGURE 19 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: VALUE CHAIN ANALYSIS

FIGURE 20 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ECOSYSTEM

ANALYSIS

FIGURE 21 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FIGURE 23 PATENT ANALYSIS FOR MOLECULAR INFECTIOUS DISEASE TESTING MARKET, JANUARY 2016–DECEMBER 2025

FIGURE 24 MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE

FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT & SERVICE

FIGURE 27 REGIONAL INCIDENCE OF HIV, 2023

FIGURE 28 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT

FIGURE 29 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT

FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023–2025 (USD MILLION)

FIGURE 31 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SHARE ANALYSIS, 2025 (GLOBAL)

FIGURE 32 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SHARE ANALYSIS, 2025 (US)

FIGURE 33 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025

FIGURE 34 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY FOOTPRINT

FIGURE 35 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025

FIGURE 36 EV/EBITDA OF KEY VENDORS

FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 38 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: BRAND/PRODUCT COMPARISON FOR MOLECULAR INFECTIOUS DISEASE TESTING

FIGURE 39 DANAHER: COMPANY SNAPSHOT (2025)

FIGURE 40 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)

FIGURE 41 BIOM?RIEUX: COMPANY SNAPSHOT (2025)

FIGURE 42 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)

FIGURE 43 ABBOTT: COMPANY SNAPSHOT (2025)
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 45 QIAGEN : COMPANY SNAPSHOT (2024)
FIGURE 46 REVVITY: COMPANY SNAPSHOT (2025)
FIGURE 47 GRIFOLS, S.A.: COMPANY SNAPSHOT (2025)
FIGURE 48 SEEGENE INC.: COMPANY SNAPSHOT (2025)
FIGURE 49 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
FIGURE 50 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025)
FIGURE 51 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025)
FIGURE 52 SD BIOSENSOR: COMPANY SNAPSHOT (2024)
FIGURE 53 RESEARCH DESIGN
FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 55 TOP-DOWN APPROACH
FIGURE 56 DATA TRIANGULATION

I would like to order

Product name: Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2031

Product link: <https://marketpublishers.com/r/M6C6709E933AEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M6C6709E933AEN.html>